ATR抑制增强胰腺癌细胞对X线和碳离子照射的细胞毒与免疫原性效应
本研究以KRAS野生型BxPC-3和KRAS突变型PANC-1两种胰腺导管腺癌细胞系为对象,采用X线和碳离子两种射线及单次与大分割剂量方案,联合ATR抑制剂、CHK1抑制剂及STING激动剂diABZI,评估细胞存活、免疫原性细胞死亡、胞质dsDNA与微核积累及免疫信号激活。结果显示ATR抑制使BxPC-3对放射细胞毒效应增敏,并增强碳离子和大分割X线(3x8 Gy)的免疫原性效应,伴随STING依赖的IFNB1分泌和炎症基因表达程序诱导及单核细胞活化;PANC-1中未见此效应,单纯放疗反而对单核细胞产生免疫抑制作用。结论支持在KRAS野生型胰腺癌中进一步评估ATR抑制联合放疗。
要点
- ATR抑制增敏BxPC-3对放射的细胞毒效应并增强碳离子及3x8 Gy X线的免疫原性。
- 效应伴随胞质dsDNA与微核积累、STING依赖IFNB1分泌及炎症基因程序诱导。
- PANC-1中单纯放疗对单核细胞呈免疫抑制,联合效应未显现。
核心结论
- ATR抑制可增强KRAS野生型PDAC细胞对放射的细胞毒和免疫原性效应,支持进一步评估ATR抑制联合放疗。
研究设计与样本
- 采用KRAS野生型BxPC-3和KRAS突变型PANC-1两种PDAC细胞系,测试X线与碳离子两种射线及单次和大分割剂量方案,联合ATR抑制剂、CHK1抑制剂和STING激动剂diABZI。
主要发现
- ATR抑制使BxPC-3对放射细胞毒效应增敏,并增强碳离子和大分割X线(3x8 Gy)的免疫原性效应。
- BxPC-3中胞质dsDNA和微核积累增加,伴STING依赖的IFNB1分泌和全基因组炎症基因表达程序诱导,最终导致单核细胞活化。
- PANC-1中未见上述效应,单纯放疗对单核细胞产生免疫抑制作用。
关键数值与推荐
- 大分割X线方案为3x8 Gy。
- 免疫激活通过将免疫细胞与PDAC细胞上清共孵育后以光谱流式细胞术分析活化标志物评估。
临床怎么用
- 对KRAS野生型胰腺癌,可考虑进一步评估ATR抑制联合放疗(尤其碳离子或大分割X线)以增强抗肿瘤免疫原性。
- KRAS突变型胰腺癌中单纯放疗可能对单核细胞呈免疫抑制,联合策略需另行验证。
局限性
- 研究仅基于两种PDAC细胞系及体外免疫细胞共孵育体系,结论需体内和临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge characterized by an alarmingly low survival rate. Despite surgical advances and new chemotherapy combinations, currently available treatment fails to improve the overall survival of PDAC patients largely due to an immunosuppressive tumor microenvironment. Radiation can induce cell death and reprogramme the tumor microenvironment by promoting anti-tumor immune response. The cGAS-STING and RIG-I-MAVS pathways are central components of the innate immune system that detect cytosolic nucleic acids and initiate type I interferon production. This study aims to leverage radiation-induced DNA damage together with inhibition of DNA repair and cell cycle checkpoints to potentiate type I interferon response and thereby enhance anti-tumor immunogenicity in PDAC. MATERIALS AND METHODS: Two different PDAC cell lines (KRAS wild-type BxPC-3 and KRAS-mutated PANC-1) were used to test two different radiation modalities (X-rays and carbon ions) and regimens (single and hypofractionated dose) in combination with ATR and CHK1 inhibitors as well as the STING agonist diABZI. Cell survival, immunogenic cell death, accumulation of cytosolic dsDNA and micronuclei, gene expression profiles, and STING- and NF-κB-dependent immune signaling were assessed. Immune activation was evaluated by incubating immune cells with supernatants from PDAC cells, followed by analysis of activation markers using spectral flow cytometry. RESULTS: Here we demonstrate that ATR inhibition sensitizes BxPC-3 cells to the cytotoxic effects of radiation and potentiates the immunogenic effects of carbon ions and hypofractionated X-rays (3x8 Gy). Increased accumulation of cytosolic dsDNA and micronuclei was coupled with STING-dependent IFNB1 secretion and genome-wide induction of inflammatory gene expression programs, ultimately resulting in the activation of monocytes. This was not the case for PANC-1 cells, where radiation alone exerted immunosuppressive effects on monocytes. CONCLUSIONS: Our results support further evaluation of ATR inhibition in combination with radiotherapy in KRAS wild-type pancreatic cancer.
引用
- Dias AB, Ohradanova-Repic A, Dupanovic A, et al. ATR inhibition sensitizes pancreatic cancer cells to cytotoxic and immunogenic effects of X-ray and carbon ion irradiation. Radiother Oncol. 2026. PMID: 42456899. doi:10.1016/j.radonc.2026.111699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。